126 results about "Hepcidin" patented technology

The present invention concerns a method for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal; a method for measuring the level of hepcidin gene expression in a vertebrate animal; and a method for regulating the production of native, bioactive hepcidin in a vertebrate animal in vivo. The present invention also concerns an antibody or fragment thereof that specifically binds to a continuous, discontinuous, and/or conformational epitope of a mature and bioactive hepcidin folded as in the native configuration; and a pharmaceutical composition that includes the antibody or a hepcidin polypeptide and that provides antimicrobial, agonistic, or antagonistic activities in vivo in a vertebrate animal.

The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.

Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

The present invention provides novel hepcidin analogues, and related methods of using these hepcidin analogues to treat or prevent a variety of diseases and disorders, including iron overload diseases such as hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.

The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.

Methods of isolating and/or analyzing hepcidin by mass spectrometry and methods of quantifying hepcidin are disclosed.

The invention discloses an expression product in series of two fish antibacterial peptide genes and an expression method thereof, relating to the gene engineering technology of marine organism, providing an expression product in series of the two fish antibacterial peptide genes and construction of an expression vector in series of two fish Hepcidin and a preparation method for the expression product in series. In the invention, two fish hepcidin genes are expressed in series by a pET32a prokaryocyte expression vector to realize the soluble expression of two antibacterial peptide hepcidin at the same time; the expression level of two antibacterial peptides in series is over 50mg/L, the soluble expression product in series is purified by a N-terminal His-Tag affinity chromatography, and then cuts off a protein label in series by enterokinase; and the cut mixture is purified by a Ni affinity chromatographic column to obtain a purified Hepcidin expression product in series. The purified expression product has obvious inhibiting effect on Staphylococcus aureus, Aeromonas hydrophila, micrococcus lysodeikticus and the like.

The present invention provides hepcidin analogues with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.

The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or down-regulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.

The invention relates to an IL-22-Fc molecule to regulate hepcidin activity/expression and/or iron export from a cell.

The invention discloses an expressing carrier of black porgy antibiotic peptide Hepcidin, expressing product and preparing method, which is characterized by the following: incorporating E. coliTrc promoter, protein project improving CKS gene and procaryotic expressing carrier pTrc-CKS of histidine tag (His-Tag); connecting to black porgy Hepcidin gene; constructing pTrc-CKS/hepcidin expressing plasmid; possessing P3C enzyme cutting site; fusing six histidine on C end; getting CKS-hepcidin; purifying through C end His-Tag affinity chromatography; getting the purified product; cutting CKS with P3C enzyme in fuse protein; getting the purified Hepcidin.

The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.

The present invention discloses a recombinant human hepcidin adenovirus (Ad-hepc), which contains human hepcidin gene and adenovirus vector. The present invention also discloses a preparation of the recombinant human hepcidin adenovirus and an application thereof. The present invention utilizes defective adenovirus to deliver the human hepcidin gene into the tissue cells of the body, so that the virus can express hepcidin protein in the body of a patient.

The invention discloses a eukaryotic fused expression product of two marine animal antibacterial peptide genes, and a preparation method thereof, and relates to genetic engineering expressions of antibacterial peptides of marine fishes and crabs. The two marine animal antibacterial peptide genes comprise mud crab antibacterial peptide scygonadin gene, a connecting peptide, large yellow croaker antibacterial peptide hepcidin gene. The preparation method comprises the following steps that: the mud crab antibacterial peptide scygonadin gene and the large yellow croaker antibacterial peptide hepcidin gene are amplified through PCR reactions; a overlap PCR reaction is adopted for preparing the target gene fragment of a combined polypeptide Scy-hepc; the resulting fusion gene Scy-hepc is inserted into an expression vector to construct a fusion gene Scy-hepc-carried recombinant expression vector; the resulting recombinant expression vector is transferred into the host cell, and then the induction expression is adopted for the host cell to obtain the expression product; the expression product is isolated and purified to obtain the recombinant protein, which is the combined polypeptide Scy-hepc.